JPWO2021127561A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021127561A5 JPWO2021127561A5 JP2022537517A JP2022537517A JPWO2021127561A5 JP WO2021127561 A5 JPWO2021127561 A5 JP WO2021127561A5 JP 2022537517 A JP2022537517 A JP 2022537517A JP 2022537517 A JP2022537517 A JP 2022537517A JP WO2021127561 A5 JPWO2021127561 A5 JP WO2021127561A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- pharmaceutically acceptable
- alkyl
- compound according
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 57
- 150000003839 salts Chemical class 0.000 claims 46
- 206010028980 Neoplasm Diseases 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 15
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 14
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 12
- 230000002159 abnormal effect Effects 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 230000010261 cell growth Effects 0.000 claims 9
- 230000035772 mutation Effects 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 150000001336 alkenes Chemical class 0.000 claims 4
- 150000001345 alkine derivatives Chemical class 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- -1 R 21 Chemical compound 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000005702 oxyalkylene group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Claims (61)
A*は、
B*は、ヘテロアリール又はアリールであり、各々が1つ、2つ又は3つのR31置換基で任意に置換され、
yは0、1、2又は3であり、
R31は、いずれの場合にもH、F、Cl、Br、I、C1~6-アルキル、シアノ、C1~6-アルコキシ、ハロ-C1~6-アルコキシ、ハロ-C1~6-アルキル、C3~8-シクロアルキル及びハロ-C3~8-シクロアルキルから独立して選択され、二環上に存在する場合に、いずれの環に位置していてもよく、
R32は水素、F、Cl、Br、I、C1~6-アルキル、ハロ-C1~6-アルキル、C3~8-シクロアルキル又はハロ-C3~8-シクロアルキルであり、
R33は水素、F、Cl、Br、I、C1~6-アルキル、ハロ-C1~6-アルキル、C3~8-シクロアルキル又はハロ-C3~8-シクロアルキルであり、ジヒドロピロール又はイミダゾール環上に位置していてもよく、
R34は、H、F、C1~6-アルキル、ハロ-C1~6-アルキル、C3~8-シクロアルキル及びハロ-C3~8-シクロアルキルから独立して選択され、
R35は、H、F、Cl、Br、I、C1~6-アルキル、ハロ-C1~6-アルキル及びC3~8-シクロアルキルから独立して選択されるか、
又はR34とR35とが結合して-(CH2)q-を形成し、
qは1又は2であり、
R36及びR37は独立して、H、F、Cl、Br、I、シアノ、C1~6-アルコキシ、ハロ-C1~6-アルコキシ、C1~6-アルキル、ハロ-C1~6-アルキル、C3~8-シクロアルキル及びハロ-C3~8-シクロアルキルから選択されるか、
又はR36とR37とが一緒に結合して、1つ、2つ又は3つのR31置換基で任意に置換された5員又は6員の環を形成し、
A 21は-NH-、-O-、-CH2-又は-NR100-であり、
R100はアルキル、シクロアルキル、アリール若しくはヘテロアリールであるか、又は原子価が許す範囲で、R100がR37と結合して5員~8員の複素環若しくは5員のヘテロアリールを形成してもよく、
A32 及びA 33は独立して、-N-及び-CR42-から選択され、
R42は、いずれの場合にもH、F、Cl、Br、I、シアノ、C1~6-アルコキシ、ハロ-C1~6-アルコキシ、C1~6-アルキル、ハロ-C1~6-アルキル、C3~8-シクロアルキル及びハロ-C3~8-シクロアルキルから独立して選択され、
L 2 が式:
X 1 及びX 2 は独立して、いずれの場合にも、結合、複素環、アリール、ヘテロアリール、二環、アルキル、-NR 27 -、-CR 40 R 41 -、-O-、-C(O)-、-C(NR 27 )-、-C(S)-、-S(O)-、-S(O) 2 -及び-S-から選択され、その複素環、アリール、ヘテロアリール及び二環の各々が、R 40 から独立して選択される1つ、2つ、3つ又は4つの置換基で任意に置換され、
R 20 、R 21 、R 22 、R 23 及びR 24 は独立して、いずれの場合にも、結合、アルキル、-C(O)-、-C(O)O-、-OC(O)-、-SO 2 -、-S(O)-、-C(S)-、-C(O)NR 27 -、-NR 27 C(O)-、-O-、-S-、-NR 27 -、オキシアルキレン、-C(R 40 R 40 )-、-P(O)(OR 26 )O-、-P(O)(OR 26 )-、二環、アルケン、アルキン、ハロアルキル、アルコキシ、アリール、複素環、ヘテロアリール、乳酸、グリコール酸及び炭素環からなる群から選択され、各々が、R 40 から独立して選択される1つ、2つ、3つ又は4つの置換基で任意に置換され、
R 26 は独立して、いずれの場合にも、水素、アルキル、アリールアルキル、ヘテロアリールアルキル、アルケン、アルキン、アリール、ヘテロアリール、及び複素環からなる群から選択され、
R 27 は独立して、いずれの場合にも、水素、アルキル、複素環、アリール、ヘテロアリール、-C(O)(アルキル、アリール、又はヘテロアリール)、-C(O)O(アルキル、アリール、又はヘテロアリール)、アルケン及びアルキンからなる群から選択され、
R 40 は独立して、いずれの場合にも、水素、R 27 、アルキル、アルケン、アルキン、フルオロ、ブロモ、クロロ、ヒドロキシル、アルコキシ、アジド、アミノ、シアノ、-NH(アルキル)、-N(アルキル) 2 、-NHSO 2 (アルキル)、-N(アルキル)SO 2 アルキル、-NHSO 2 (アリール、ヘテロアリール又は複素環)、-N(アルキル)SO 2 (アリール、ヘテロアリール又は複素環)、-NHSO 2 アルケニル、-N(アルキル)SO 2 アルケニル、-NHSO 2 アルキニル、-N(アルキル)SO 2 アルキニル、ハロアルキル、アリール、ヘテロアリール、複素環、オキソ及びシクロアルキルからなる群から選択されるか、或いは、原子価が許す場合に、同じ炭素に結合した2つのR 40 基が一体となって3員~8員のスピロ環を形成してもよく、
R 41 はアルキル、アリール、ヘテロアリール又は水素である)の二価連結基である)
の化合物又はその薬学的に許容可能な塩。 Formula III :
A * is
B * is heteroaryl or aryl, each optionally substituted with 1, 2 or 3 R substituents ;
y is 0, 1, 2 or 3,
In each case, R 31 is H , F , Cl, Br, I, C 1-6 -alkyl, cyano, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, halo-C 1- independently selected from 6 -alkyl, C 3-8 -cycloalkyl and halo-C 3-8 -cycloalkyl, which when present on the bicyclic ring may be located on either ring;
R 32 is hydrogen , F , Cl, Br, I, C 1-6 -alkyl, halo-C 1-6 -alkyl, C 3-8 -cycloalkyl or halo-C 3-8 -cycloalkyl,
R 33 is hydrogen , F , Cl, Br, I, C 1-6 -alkyl, halo-C 1-6 -alkyl, C 3-8 -cycloalkyl or halo-C 3-8 -cycloalkyl, may be located on the dihydropyrrole or imidazole ring,
R 34 is independently selected from H 1 , F, C 1-6 -alkyl, halo-C 1-6 -alkyl, C 3-8 -cycloalkyl and halo-C 3-8 -cycloalkyl;
R 35 is independently selected from H, F , Cl, Br, I, C 1-6 -alkyl, halo-C 1-6 -alkyl and C 3-8 -cycloalkyl;
or R 34 and R 35 combine to form -(CH 2 ) q -,
q is 1 or 2,
R 36 and R 37 are independently H , F , Cl, Br, I, cyano, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, C 1-6 -alkyl, halo-C 1 selected from ~6 -alkyl, C3-8 -cycloalkyl and halo- C3-8 -cycloalkyl,
or R 36 and R 37 are joined together to form a 5- or 6-membered ring optionally substituted with one, two or three R 31 substituents ;
A 21 is -NH-, -O-, -CH 2 - or -NR 100 -,
R 100 is alkyl, cycloalkyl, aryl, or heteroaryl, or, to the extent permitted by valence, R 100 is combined with R 37 to form a 5- to 8-membered heterocycle or a 5-membered heteroaryl. It's okay,
A 32 and A 33 are independently selected from -N- and -CR 42 -;
In each case, R 42 is H , F , Cl, Br, I, cyano, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, C 1-6 -alkyl, halo-C 1- independently selected from 6 -alkyl, C 3-8 -cycloalkyl and halo-C 3-8 -cycloalkyl,
L2 is the formula:
X 1 and X 2 are independently, in each case, a bond, heterocycle, aryl, heteroaryl, bicyclic, alkyl, -NR 27 -, -CR 40 R 41 -, -O-, -C( O)-, -C(NR 27 )-, -C(S)-, -S(O)-, -S(O) 2 - and -S-, and its heterocycle, aryl, heteroaryl and each of the two rings is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 40 ;
R 20 , R 21 , R 22 , R 23 and R 24 independently in each case represent a bond, alkyl, -C(O)-, -C(O)O-, -OC(O)- , -SO 2 -, -S(O)-, -C(S)-, -C(O)NR 27 -, -NR 27 C(O)-, -O-, -S-, -NR 27 - , oxyalkylene, -C(R 40 R 40 )-, -P(O)(OR 26 )O-, -P(O)(OR 26 )-, bicyclic, alkene, alkyne, haloalkyl, alkoxy, aryl, selected from the group consisting of heterocycle, heteroaryl, lactic acid, glycolic acid and carbocycle, each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 40 ,
R 26 is independently selected in each case from the group consisting of hydrogen, alkyl, arylalkyl, heteroarylalkyl, alkene, alkyne, aryl, heteroaryl, and heterocycle;
R 27 is independently in each case hydrogen, alkyl, heterocycle, aryl, heteroaryl, -C(O)(alkyl, aryl, or heteroaryl), -C(O)O(alkyl, aryl). , or heteroaryl), alkenes and alkynes;
R 40 is independently in each case hydrogen, R 27 , alkyl, alkene, alkyne, fluoro, bromo, chloro, hydroxyl, alkoxy, azide, amino, cyano, -NH(alkyl), -N(alkyl) ) 2 , -NHSO 2 (alkyl), -N(alkyl)SO 2alkyl , -NHSO 2 (aryl, heteroaryl or heterocycle), -N(alkyl)SO 2 (aryl, heteroaryl or heterocycle), - selected from the group consisting of NHSO2alkenyl , -N(alkyl)SO2alkenyl , -NHSO2alkynyl , -N ( alkyl) SO2alkynyl , haloalkyl, aryl, heteroaryl, heterocycle, oxo and cycloalkyl, Alternatively, if valence permits, two R40 groups bonded to the same carbon may join together to form a 3- to 8-membered spiro ring;
R 41 is a divalent linking group of alkyl, aryl, heteroaryl or hydrogen)
or a pharmaceutically acceptable salt thereof.
から選択される、請求項1に記載の化合物又はその薬学的に許容可能な塩。 2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from:
BB ** は、1つ、2つ又は3つのRis one, two or three R 3131 置換基で任意に置換される、アリール又はヘテロアリールであり、aryl or heteroaryl, optionally substituted with a substituent;
Yは、0、1、2又は3であり、Y is 0, 1, 2 or 3;
RR 3131 は、いずれの場合にもH、F、Cl、Br、I、CIn any case, H, F, Cl, Br, I, C 1~61-6 -アルキル、シアノ、C-Alkyl, cyano, C 1~61-6 -アルコキシ、ハロ-C-Alkoxy, halo-C 1~61-6 -アルコキシ、ハロ-C-Alkoxy, halo-C 1~61-6 -アルキル、C-Alkyl, C 3~83-8 -シクロアルキル及びハロ-C-cycloalkyl and halo-C 3~83-8 -シクロアルキルから独立して選択され、二環上に存在する場合に、いずれの環に位置していてもよく、- independently selected from cycloalkyl, which when present on a bicyclic ring may be located on either ring;
RR 3232 は水素、F、Cl、Br、I、Cis hydrogen, F, Cl, Br, I, C 1~61-6 -アルキル、ハロ-C-Alkyl, halo-C 1~61-6 -アルキル、C-Alkyl, C 3~83-8 -シクロアルキル又はハロ-C-cycloalkyl or halo-C 3~83-8 -シクロアルキルであり、- cycloalkyl;
RR 3333 は水素、F、Cl、Br、I、Cis hydrogen, F, Cl, Br, I, C 1~61-6 -アルキル、ハロ-C-Alkyl, halo-C 1~61-6 -アルキル、C-Alkyl, C 3~83-8 -シクロアルキル又はハロ-C-cycloalkyl or halo-C 3~83-8 -シクロアルキルであり、ジヒドロピロール又はイミダゾール環上に位置していてもよい)- cycloalkyl, optionally located on the dihydropyrrole or imidazole ring)
のものである、請求項1に記載の化合物又はその薬学的に許容可能な塩。2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962951467P | 2019-12-20 | 2019-12-20 | |
US201962951464P | 2019-12-20 | 2019-12-20 | |
US62/951,467 | 2019-12-20 | ||
US62/951,464 | 2019-12-20 | ||
PCT/US2020/066211 WO2021127561A1 (en) | 2019-12-20 | 2020-12-18 | Isoindolinone and indazole compounds for the degradation of egfr |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023509375A JP2023509375A (en) | 2023-03-08 |
JPWO2021127561A5 true JPWO2021127561A5 (en) | 2023-12-26 |
Family
ID=76478832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022537517A Pending JP2023509375A (en) | 2019-12-20 | 2020-12-18 | Isoindolinone and indazole compounds for the degradation of EGFR |
Country Status (15)
Country | Link |
---|---|
US (2) | US11673902B2 (en) |
EP (1) | EP4076450A4 (en) |
JP (1) | JP2023509375A (en) |
KR (1) | KR20220119415A (en) |
CN (1) | CN114901277B (en) |
AU (1) | AU2020405237A1 (en) |
BR (1) | BR112022011827A2 (en) |
CA (1) | CA3154073A1 (en) |
CL (1) | CL2022001641A1 (en) |
CO (1) | CO2022008604A2 (en) |
IL (1) | IL293999A (en) |
MX (1) | MX2022007659A (en) |
PE (1) | PE20221724A1 (en) |
TW (1) | TW202136265A (en) |
WO (1) | WO2021127561A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022280070A1 (en) * | 2021-05-26 | 2023-11-16 | C4 Therapeutics, Inc. | Egfr degraders to treat cancer metastasis to the brain or cns |
EP4367113A1 (en) | 2021-07-07 | 2024-05-15 | Biogen MA Inc. | Compounds for targeting degradation of irak4 proteins |
TW202329964A (en) | 2021-11-17 | 2023-08-01 | 大陸商浙江同源康醫藥股份有限公司 | Compound for degrading EGFR protein and use thereof |
TW202333670A (en) * | 2022-01-04 | 2023-09-01 | 大陸商海思科醫藥集團股份有限公司 | Compound for inhibiting and degrading irak4, and pharmaceutical composition and pharmaceutical application thereof |
CN115109055B (en) * | 2022-05-26 | 2023-11-28 | 北京康辰药业股份有限公司 | Difunctional compound for EGFR degradation and application thereof |
CN115160311B (en) * | 2022-05-26 | 2024-03-15 | 北京康辰药业股份有限公司 | Difunctional compound for EGFR degradation and application thereof |
WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
WO2024097994A1 (en) * | 2022-11-03 | 2024-05-10 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of non-small-cell lung cancer |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
ATE522518T1 (en) * | 2006-05-31 | 2011-09-15 | Takeda San Diego Inc | INDAZOLE AND ISOINDOLE DERIVATIVES AS GLUCOKINASE ACTIVATE SUBSTANCES |
US9500653B2 (en) | 2010-12-07 | 2016-11-22 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
CN104736569A (en) | 2012-01-12 | 2015-06-24 | 耶鲁大学 | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
CN105073768A (en) | 2013-03-13 | 2015-11-18 | 达纳-法伯癌症研究所股份有限公司 | Ras inhibitors and uses thereof |
AU2015247817C1 (en) | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
US20160022642A1 (en) | 2014-07-25 | 2016-01-28 | Yale University | Compounds Useful for Promoting Protein Degradation and Methods Using Same |
US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
WO2016065139A1 (en) | 2014-10-24 | 2016-04-28 | Fl Therapeutics Llc | 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin |
US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
EP3256470B1 (en) | 2014-12-23 | 2023-07-26 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
CA2979070A1 (en) | 2015-03-18 | 2016-09-22 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
CN108136044B (en) | 2015-06-04 | 2021-08-10 | 阿尔维纳斯运营股份有限公司 | Imide-based proteolytic modulators and related methods of use |
CA2987914C (en) * | 2015-06-30 | 2022-09-13 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
BR112018008918A8 (en) | 2015-11-02 | 2019-02-26 | Univ Yale | directed proteolysis chimera compounds and methods for their preparation and use |
AU2017232906B2 (en) | 2016-03-16 | 2022-03-31 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Small molecules against cereblon to enhance effector T cell function |
AU2017254713C1 (en) * | 2016-04-22 | 2021-04-29 | Dana-Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of EGFR and methods of use |
WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
CA3025806C (en) | 2016-06-23 | 2023-04-04 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use |
CN110381997A (en) * | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | For treating and preventing the method and composition comprising gene-virus therapy and immunologic test point inhibitor of cancer and infectious diseases |
CA3043938A1 (en) | 2016-12-21 | 2018-06-28 | Biotheryx, Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
TW201834651A (en) * | 2016-12-22 | 2018-10-01 | 瑞士商赫孚孟拉羅股份公司 | Compounds |
BR112019012878A2 (en) | 2016-12-23 | 2019-11-26 | Arvinas Operations Inc | compounds and methods for target degradation of rapidly accelerated fibrosarcoma polypeptides |
BR112019012682A2 (en) * | 2016-12-23 | 2019-12-17 | Arvinas Operations Inc | chimeric molecules targeting egfr proteolysis and associated methods of use |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
BR112019015484A2 (en) | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | cereblon ligands and bifunctional compounds comprising the same |
WO2018220149A1 (en) * | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Compounds |
WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
MX2020003190A (en) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Protein degraders and uses thereof. |
US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
TW201945357A (en) * | 2018-02-05 | 2019-12-01 | 瑞士商赫孚孟拉羅股份公司 | Compounds |
MX2020014085A (en) * | 2018-06-29 | 2021-03-09 | Hoffmann La Roche | Compounds. |
-
2020
- 2020-12-18 CA CA3154073A patent/CA3154073A1/en active Pending
- 2020-12-18 JP JP2022537517A patent/JP2023509375A/en active Pending
- 2020-12-18 TW TW109145179A patent/TW202136265A/en unknown
- 2020-12-18 WO PCT/US2020/066211 patent/WO2021127561A1/en active Application Filing
- 2020-12-18 PE PE2022001139A patent/PE20221724A1/en unknown
- 2020-12-18 KR KR1020227024551A patent/KR20220119415A/en unknown
- 2020-12-18 AU AU2020405237A patent/AU2020405237A1/en active Pending
- 2020-12-18 CN CN202080088015.1A patent/CN114901277B/en active Active
- 2020-12-18 IL IL293999A patent/IL293999A/en unknown
- 2020-12-18 MX MX2022007659A patent/MX2022007659A/en unknown
- 2020-12-18 EP EP20902413.2A patent/EP4076450A4/en active Pending
- 2020-12-18 BR BR112022011827A patent/BR112022011827A2/en unknown
-
2022
- 2022-06-16 CL CL2022001641A patent/CL2022001641A1/en unknown
- 2022-06-17 CO CONC2022/0008604A patent/CO2022008604A2/en unknown
- 2022-06-17 US US17/843,769 patent/US11673902B2/en active Active
-
2023
- 2023-05-08 US US18/144,800 patent/US20240076300A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI796526B (en) | Pd-1/pd-l1 inhibitors | |
AU2023202592A1 (en) | Modulators of the integrated stress pathway | |
EP3704089B1 (en) | Modulators of the integrated stress pathway | |
JP6474068B2 (en) | 2-Aminopyrimidine compounds and drug compositions and uses thereof | |
US20220396585A1 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 | |
ES2378640T3 (en) | Polymorph B of N- (2-aminophenyl) -4- [N- (pyridin-3-yl) methoxycarbonylaminomethyl] benzamide (MS-275) | |
JP2020510015A5 (en) | ||
TW201808958A (en) | Chemokine receptor modulators and uses thereof | |
RU2015118647A (en) | AMINOPYRIMIDINE COMPOUNDS AS T790M MUTANT EGFR INHIBITORS | |
JPWO2020075790A1 (en) | STING working compound | |
JP2014503567A5 (en) | ||
WO2013184766A1 (en) | Compounds and compositions for modulating egfr activity | |
JP2016525104A5 (en) | ||
JPWO2021127561A5 (en) | ||
JP2022541330A (en) | Macrocycles as STING agonists and methods and uses thereof | |
JP2017532294A5 (en) | ||
JP2018535980A (en) | Thieno-pyrimidine derivatives and uses thereof | |
RU2015141591A (en) | BRUTON TYROSINKINASE INHIBITORS | |
JP2004536079A5 (en) | ||
JP2024514879A (en) | MEK inhibitors and their uses | |
US20190084980A1 (en) | Amide-Sulfamide Derivatives, Compositions, and Uses Related to CXCR4 Inhibition | |
JP2013521316A5 (en) | ||
JP2012528184A5 (en) | ||
CN112062717A (en) | Indoleamine 2, 3-dioxygenase inhibitor | |
WO2024053650A1 (en) | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST DIACYLGLYCEROL KINASE α AND/OR ζ, AND PHARMACEUTICAL USE THEREOF |